Skip to content
Important: This site presents data from the FDA Adverse Event Reporting System (FAERS). A report does not mean the drug caused the event. Full disclaimer.

AMPYRA for Relapsing-remitting multiple sclerosis: Side Effects & Safety Data

Boost Your Natural Energy & Metabolism

Mitolyn — 6 exotic plants to unlock your body's fat-burning power. 90-day guarantee.

Try Mitolyn Now

There are 9 adverse event reports in the FDA FAERS database where AMPYRA was used for Relapsing-remitting multiple sclerosis.

Most Reported Side Effects for AMPYRA

Side Effect Reports % Deaths Hosp.
Drug ineffective 711 18.0% 2 16
Gait disturbance 518 13.1% 4 21
Dizziness 354 9.0% 0 6
Insomnia 313 7.9% 0 3
Balance disorder 262 6.6% 1 10
Headache 247 6.2% 1 8
Nausea 233 5.9% 0 7
Fall 208 5.3% 3 31
Fatigue 185 4.7% 4 5
Asthenia 179 4.5% 2 18
Inappropriate schedule of drug administration 178 4.5% 3 9
Urinary tract infection 166 4.2% 5 30
Drug dose omission 162 4.1% 0 14
Multiple sclerosis relapse 159 4.0% 3 49
Back pain 145 3.7% 1 13

Other Indications for AMPYRA

Product used for unknown indication (1,872) Gait disturbance (1,453) Multiple sclerosis (646) Balance disorder (40) Muscular weakness (16) Asthenia (15) Fatigue (15) Ataxia (11) Muscle spasticity (7) Peroneal nerve palsy (6)

Other Drugs Used for Relapsing-remitting multiple sclerosis

OCRELIZUMAB (15,658) FINGOLIMOD (8,814) OFATUMUMAB (3,864) DIMETHYL (3,638) NATALIZUMAB (2,749) INTERFERON BETA-1A (2,058) GLATIRAMER (1,965) ALEMTUZUMAB (1,604) TERIFLUNOMIDE (1,320) RITUXIMAB (956)

Related Pages

AMPYRA Full Profile All Relapsing-remitting multiple sclerosis Drugs AMPYRA Demographics AMPYRA Timeline